Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047645 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3 study, sponsored by InterMune.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT00047645 is a Phase 3 study that has completed, run by InterMune. The registered enrollment target is 330 participants.
The verdict
NCT00047645, a Phase 3 study, has completed, sponsored by InterMune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.
Interventions
- DRUG Interferon-gamma 1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2000-04 |
| Est. Completion | 2002-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047645
The ClinicalTrials.gov registry entry for NCT00047645 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon-gamma 1b is the first listed.
NCT00047645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047645 about?
NCT00047645 is a clinical study titled "A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group...
What is the current status of trial NCT00047645?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2000-04. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00047645?
The interventions under investigation include: Interferon-gamma 1b (DRUG).
Who is sponsoring clinical trial NCT00047645?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.